Identity in medicine and pharmaceuticals: requirements and limitations
Where does the conversation about pharmaceutical identity begin
The basic document in Russia is the methodological guidelines MU 9467-015-05749470-98 on the graphical design of medicinal products, and the requirements for labeling are set forth in article 46 of Federal Law No. 61-FZ "On the Circulation of Medicinal Products". The logic is simple: the packaging is the only information carrier that a patient sees at the moment when it is no longer possible to consult a doctor, often at night and in a hurry. Hence the rule that contradicts the intuition of a brand manager: for the entire product line of one drug, a single color and font solution is required, and for different dosages of the same product — a unified artistic image, but different colors. A patient must be able to recognize their medicine by the common style of the box, and at the same time not confuse 5 mg tablets with 50 mg tablets.
What exactly do GRLS, Rospotrebnadzor, Roszdravnadzor require — and how do they differ from FDA and EMA
Formal requirements are so specific that they turn package design into an engineering task:
- The name of the drug on the primary packaging cannot be printed in different font colors — this is a direct path to confusion.
- The label with the batch number and expiration date must not exceed 1/6 of the secondary packaging area — the remaining space is reserved for mandatory information.
- The minimum font size is 7 points, the height of the lowercase letter 'x' is no less than 1,4 mm, the color of the inscription is contrasted with the background.
- Gloss and 'metallic' coating are prohibited — they create a glare under side lighting, which is critical for elderly patients.
FDA is going further and regulating composition: the logo and any graphics cannot be located between the proprietary name and the established name — both must be in the same field of view, and the type size of the established name must not be less than half the type size of the proprietary name. EMA adds a requirement that does not exist in Russian practice: according to Directive 2001/83/EC, article 56a, the secondary packaging of a medicine sold in the EU must include a Braille font with the name and dosage — this is a separate line item in the prepress budget, which Russian clients of agencies usually do not know about until they enter the European market.
| Requirement | Russia (MU 9467, GRLS) | USA (FDA) | EU (EMA) |
|---|---|---|---|
| Different colors for different dosages | Required | Recommended via USP | Required for high-risk drugs |
| Proportion of proprietary and established names | Regulated more loosely | Strict: established name not less than ½ the type size of the proprietary name | Strict: both names in the same field of view |
| Braille font | Not required | Not required | Required (Directive 2001/83/EC) |
| Gloss and 'metallic' | Prohibited | Not regulated separately | Limited for prescription drugs |
How they visually prevent confusion of drugs
Tall Man Lettering
One of the most practical technologies in pharmaceutical design is hardly known outside the industry — Tall Man Lettering, writing part of the letters in the name in uppercase to visually distinguish similar words: hydrOXYzine and hydrALAzine, DOPamine and DOBUTamine. The Institute for Safe Medication Practices (ISMP) in the USA maintains an official list of drug pairs that are most commonly confused, and recommends this specific spelling on labels and in electronic prescriptions. This practice is not yet established by regulation in Russia, but manufacturers of generic drugs are increasingly adopting it voluntarily — because complaints about confusion of names with similar sounds are real and appear in reports from Roszdravnadzor on undesirable effects.
Color and dosage
The requirement of the MU 9467 for different colors for different dosages is not a bureaucratic formality, but a direct protection against overdose: a patient who has been taking the 'blue box' for years will automatically take the blue box again, even if the doctor has increased the dose and the packaging should be a different color this time. A separate area of risk is green: it is used less frequently in prescription pharmacy than in the dietary supplements and wellness segments,
Where does the conversation about pharmaceutical identity begin
The basic document in Russia is the methodological guidelines MU 9467-015-05749470-98 on the graphical design of medicinal products, and the requirements for labeling are set forth in article 46 of Federal Law No. 61-FZ "On the Circulation of Medicinal Products". The logic is simple: the packaging is the only information carrier that a patient sees at the moment when it is no longer possible to consult a doctor, often at night and in a hurry. Hence the rule that contradicts the intuition of a brand manager: for the entire product line of one drug, a single color and font solution is required, and for different dosages of the same product — a unified artistic image, but different colors. A patient must be able to recognize their medicine by the common style of the box, and at the same time not confuse 5 mg tablets with 50 mg tablets.
What exactly do GRLS, Rospotrebnadzor, Roszdravnadzor require — and how do they differ from FDA and EMA
Formal requirements are so specific that they turn package design into an engineering task:
- The name of the drug on the primary packaging cannot be printed in different font colors — this is a direct path to confusion.
- The label with the batch number and expiration date must not exceed 1/6 of the secondary packaging area — the remaining space is reserved for mandatory information.
- The minimum font size is 7 points, the height of the lowercase letter 'x' is no less than 1,4 mm, the color of the inscription is contrasted with the background.
- Gloss and 'metallic' coating are prohibited — they create a glare under side lighting, which is critical for elderly patients.
FDA is going further and regulating composition: the logo and any graphics cannot be located between the proprietary name and the established name — both must be in the same field of view, and the type size of the established name must not be less than half the type size of the proprietary name. EMA adds a requirement that does not exist in Russian practice: according to Directive 2001/83/EC, article 56a, the secondary packaging of a medicine sold in the EU must include a Braille font with the name and dosage — this is a separate line item in the prepress budget, which Russian clients of agencies usually do not know about until they enter the European market.
| Requirement | Russia (MU 9467, GRLS) | USA (FDA) | EU (EMA) |
|---|---|---|---|
| Different colors for different dosages | Required | Recommended via USP | Required for high-risk drugs |
| Proportion of proprietary and established names | Regulated more loosely | Strict: established name not less than ½ the type size of the proprietary name | Strict: both names in the same field of view |
| Braille font | Not required | Not required | Required (Directive 2001/83/EC) |
| Gloss and 'metallic' | Prohibited | Not regulated separately | Limited for prescription drugs |
How they visually prevent confusion of drugs
Tall Man Lettering
One of the most practical technologies in pharmaceutical design is hardly known outside the industry — Tall Man Lettering, writing part of the letters in the name in uppercase to visually distinguish similar words: hydrOXYzine and hydrALAzine, DOPamine and DOBUTamine. The Institute for Safe Medication Practices (ISMP) in the USA maintains an official list of drug pairs that are most commonly confused, and recommends this specific spelling on labels and in electronic prescriptions. This practice is not yet established by regulation in Russia, but manufacturers of generic drugs are increasingly adopting it voluntarily — because complaints about confusion of names with similar sounds are real and appear in reports from Roszdravnadzor on undesirable effects.
Color and dosage
The requirement of the MU 9467 for different colors for different dosages is not a bureaucratic formality, but a direct protection against overdose: a patient who has been taking the 'blue box' for years will automatically take the blue box again, even if the doctor has increased the dose and the packaging should be a different color this time. A separate area of risk is green: it is used less frequently in prescription pharmacy than in the dietary supplements and wellness segments,
Recent articles
MegaFon, BMW, VTB and more 240+ companies. See how it looks in the showcase reel:
Our branding agency is approached to order:
Branding agency services
